CDMO – Contract manufacturing

TBD Pharmatech’s Välja facility, fully operational and EU-GMP-licensed from Q4 2025, provides a dedicated platform for commercial API production following development or technology transfer. The 3,000 m² site in Tartu houses ten purpose-built GMP production suites equipped with glass-lined reactors up to 1,000 L, integrated isolation and drying systems, and segregated personnel and material flows to ensure contamination-controlled operations. Designed to support both complex chemistries and high-volume campaigns, Välja strengthens EU-based supply security while offering built-in capacity for future expansion. Whether scaling a process developed at our Tiigi site or transferring an established manufacturing route, we deliver routine cGMP production, process validation, and Qualified Person batch release within a unified quality system — ensuring predictable timelines, lot-to-lot consistency, and transparent project oversight.

Facilities